Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Alnylam Pharmaceuticals (ALNY) is 9/10.
Alnylam surpassed $1 billion in quarterly product revenue for the first time with Q1 sales growing 121% year-over-year, as TTR franchise revenue reached $910 million driven by strengthening first-line AMVUTTRA adoption in ATTR-CM. The company delivered its third consecutive quarter of both GAAP and non-GAAP profitability, confirming the sustainable economics of the RNAi platform at scale. Management reiterated 2026 guidance as presented at the prior earnings call.
Scored from Alnylam Pharmaceuticals’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $593M | +34.9% | $-0.65 | +40.9% | -17.7% | -14.1% | $-104M |
| FY2025 Q1 | $594M | +20.2% | $-0.44 | +15.4% | 3.0% | -9.7% | $-127M |
| FY2025 Q2 | $774M | +17.3% | $-0.51 | -292.3% | -2.1% | -8.6% | $139M |
| FY2025 Q3 | $1.25B | +149.3% | $1.84 | +311.5% | 29.5% | 20.1% | $313M |
| FY2025 Q4 | $1.10B | +84.9% | $1.37 | +310.8% | 12.0% | 17.0% | $140M |
| FY2026 Q1 | $1.17B | +96.4% | $1.51 | +443.2% | 23.0% | 17.6% | $49M |
| FY2026 Q2 | $1.29B | +66.9% | $1.20 | +335.3% | 17.9% | 12.7% | $292M |